- It is intended for research use only
- The total assay time is less than 2.5 hours
- The kit measures hsa-miR-155-5p isolated from human blood
- Assay format is 96 wells
- Standard is synthetic miRNA-based
- Components of the kit are provided ready to use, concentrated or dried
Immune Response, Infection and Inflammation, Oncology
MicroRNAs (miRNAs) are small non-coding RNA molecules, approximately 22 nucleotides in length that regulate gene translation through silencing or degradation of target mRNAs. They are involved in multiple biological processes, including differentiation and proliferation, metabolism, hemostasis, apoptosis or inflammation, and in pathophysiology of many diseases. Numerous studies have suggested circulating miRNAs as promising diagnostic and prognostic biomarkers of many diseases.
MicroRNA-155 is encoded by the MIR155 host gene (MIR155HG). MiR-155 is mainly expressed in the thymus and spleen; in the other tissues, its expression is negligible/undetectableunder normal physiological conditions. Target genes that are regulated by miR-155 include approximately 140 genes that encode for immunomodulatory proteins, tumor-suppressor proteins, and inﬂammatory-related proteins. Therefore, miR-155 is often associated with disorders, including cardiovascular diseases, inﬂammation, and cancer.
It is well-known that miR-155-5p is a proinﬂammatory, oncogenic miRNA, highly expressed in activated B and T cells as well as in macrophagesmiR-155-5p controls the function of lymphocytes and dendritic cells and is critical for normal immune function. In the gastrointestinal tract, abnormal miR-155 expression can be detected during Helicobacter pylori infection, and increased expression is observed in patients with inﬂammatory bowel disease (IBD) and colorectal cancer (CRC).
miR-155 can be detected in high levels in several solid tumors such as lung cancer, breast cancer, thyroid carcinoma, cervical cancer, and pancreatic cancer and it also serves as an indicator of poor prognosis for patients with these tumors. It promotes loss of genomic integrity in cancer cells by targeting genes involved in microsatellite instability and DNA repair, which strengthens the oncogenic features of miR-155 and highlights its role at the early steps of tumorigenesis.
Recently, numerous studies have demonstrated that miR-155 is associated also with hematological malignancies. Dysregulation of miR-155-5p expression has been linked to chronic lymphocytic leukemia (CLL) pathogenesis and miR-155-5p seems to be a promising, independent biomarker of unfavorable prognosis in CLL.